July 19 (UPI) — The drug abelacimab prevents blood clots in patients undergoing knee replacement surgery, a study published by the New England Journal of Medicine found. Abelacimab, developed by Cambridge, Mass.-based Anthos Therapeutics, reduced the risk for blood clots in people who had the procedure by about 80% compared with the blood-thinner enoxaparin, the data showed.

Dr. Ryan Mathis is the Vice President of Commercial Strategy at PolarityTE, focusing on bringing regenerative medicine into clinical practice, particularly for treating diabetic foot ulcers and other forms of complex wounds. Ryan says, “So, we’re trying to solve this problem by developing SkinTE, which is revolutionizing the science for these hard-to-close wounds. The product itself […]

An unusual factor XI inhibitor Novartis had given up on might have a shot at approval after all. Abelacimab, now in development by the private company Anthos Therapeutics, has shown the utility of this mechanism by scoring in a mid-stage trial in preventing venous thromboembolism. The highest two of three doses of the project beat […]